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To date there are no published data on pharmacokinetics (PK) of
MMF in children undergoing AlloSCT. The objective of this study
is to evaluate effects of age on the PK of MMF in pediatric
AlloSCT pts. From 1/04-9/05 we enrolled 26 pediatric AlloSCT
with 23 being evaluable: mean age 7.6 yrs; wt 31.6 kg; M:F 
11:12; NBL PR (n  3), SCD (n  2), AML (CR1 [n  3], CR2
[n 1], CR3 [n 1], relapsed/induction failure [n 2]), SAA (n
4), CML CP (n  1), ALL (CR1 [n  1], CR2 [n  2], CR3 [n 
1]), HD CR2 (n  1), ALCL refractory (n  1); donor sources:
MFD (6/6 PBSC [n  6], 6/6 BM [n  2], 5/6 PBSC [n  2]), 6/6
related CB (n  1), UCB (6/6 [n  2], 5/6 [n  2], 4/6 [n  7]),
and 8/10 MUD PBSC (n  1). Cohort 1 (6 yrs) (n  8); 2 (6-12
yrs of age) (n  8); 3 (12-16 yrs) (n  7). GVHD prophylaxis
included tacrolimus (starting on day 1 or 1st day of conditioning
to maintain concentrations 5-20 ng/mL) and MMF (900 mg/m2/
dose IV Q6h starting on day1, then converted to PO [same dose]
after day 14). Serum samples for MPA assay were drawn on day
1, 7, and 14 at hour 0, 0.5, 1, 2, 3, 4, and 6 post-dose. MPA
plasma concentrations were determined by reverse-phase HPLC.
MMF dose was adjusted to maintain MPA trough 1-3.5 mg/L. The
mean CD34 cell dose/kg  25.8  105, TNC dose/kg  48 
107. Time to neutrophil (ANC 500/mm3  2 d) and platelet
engraftment (untransfused count20K  7 d) were 22 d and 39 d.
The mean f/u was 278 d. Mean MPA PK on day 14: Cmax 
12.4 mg/L, total MPA trough  0.9 mg/L, AUC0-12  32.7 mg 
hr/L, Css  2.7 mg/L, T1/2  1.5 h , Vss  1.8 L/kg, and CL 
1.4 L/kg/h at a mean MMF dose of 1080 mg/m2 IV Q6h. The
breakdown of age cohorts is shown in Table 1. Incidence of GI
adverse events attributable to MMF was 65% (nausea/vomiting
[n  12], diarrhea [n  7], abdominal pain [n  3], pneumatosis
intestinalis [n  1], colitis [n  1]). Incidence of grade II-IV
aGVHD was 59% (13/22 evaluable pts) and cGVHD was 26.3%
(5/19 evaluable pts). Kaplan-Meier probability of 1 year OS was
70.4% (CI: 49.7-91.1%). In comparison to MMF PK in adult
AlloSCT pts receiving cyclosporine/MMF (Nash et al, Biol Blood
Marrow Transplant, 2005), children have signiﬁcantly higher MMF
clearance rates (1.4 vs 0.54 L/kg/h). MMF doses 	3-fold higher
than those used in pediatric SOT recipients were required to
achieve AUC0-12  30-60 mg  h/L. Short half-life (1.5 hrs) and
rapid clearance of MMF in pediatric AlloSCT pts may be related to
a lack of enterohepatic recycling and enhanced UDP-glucurono-
syltransferase activity (Table 1).
Table 1. Mean Age-Related IV MMF PK on Day 14
Age
Group
Cmax
(mg/L)
Total
MPA
Trough
(mg/L)
Free
MPA
Trough
(ng/mL)
AUC 0–12
(mg  hr/L)
Total
Css
(mg/L)
T1/2
(hr)
CL
(L/kg/hr)
<6 y.o. (n  6) 12.2 1.0 18.7 34.0 2.8 1.8 1.6
6–12 y.o. (n  5) 11.8 0.4 14.8 29.5 2.5 1.1 1.4
12–16 y.o. (n  2) 14.4 1.4 17.9 39.9 3.3 1.5 0.6
Cmax  peak concentration; MPA  mycophenolic acid; AUC 
area under the curve; Css steady state concentration; T1/2
half-life; CL  clearance.
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THE ROLE OF MHC CLASS II IN CD4CD25 T CELL-MEDIATED FACIL-
ITATION OF ALLOGENEIC HEMATOPOIETIC ENGRAFTMENT AND SUP-
PRESSION OF GVHD
Hanash, A.M., Jones, A., Levy, R.B. University of Miami Miller School
of Medicine, Miami, FL.
In recent years there has been signiﬁcant interest in the potential
of CD4CD25 regulatory T cells to suppress GVHD and pro-
mote allogeneic engraftment. In a MHC-mismatched model uti-
lizing C57BL/6 (B6) T cell-depleted bone marrow and sublethally
conditioned (7.0 Gy TBI) BALB/c recipients, we have demon-
strated that co-transplanted donor CD4CD25 T cells are capa-
ble of supporting multi-potential and lineage-committed donor
progenitor activity as well as long-term chimerism and tolerance.
Little is currently understood regarding the antigen recognition
initiating regulatory cell function during hematopoietic transplan-
tation, and we have employed our in vivo model toward elucidating
the antigenic requirements involved in the initial promotion of
allogeneic engraftment. Transplanting BALB/c  B6 F1
CD4CD25 T cells (1  106) with B6 marrow (2  106) signif-
icantly increased B6 CFU-GM in BALB/c recipients seven days
post-BMT (P  .001 vs. BM alone), demonstrating that donor
CD4CD25 T cells did not require alloreactivity to support
hematopoietic progenitors. Furthermore, B6 CD4CD25 T cells
failed to augment MHC-disparate C3H/HeJ CFU-GM in BALB/c
recipients (P 	 .05 vs. BM alone), suggesting that donor
CD4CD25 T cells might require recognition of syngeneic
MHC for progenitor support. Indeed, augmentation of donor
CFU-GM was abrogated when B6 CD4CD25 T cells were
co-transplanted with B6-MHC class II/ marrow into BALB/c
recipients (P 	 .05 vs. BM alone). CD4CD25 T cell-mediated
augmentation of donor chimerism two months post-BMT was also
abrogated by co-transplantation with MHC II/ marrow. In
order to compare the role of MHC class II in progenitor support
vs. suppression of GVHD, a model of CD8-mediated GVHD was
utilized: co-transplanted BALB/c CD4CD25 T cells were able
to prevent the GVHD mediated by highly puriﬁed BALB/c CD8
T cells in B6-wt recipients, but failed to control the GVH reaction
that occurred in B6-MHC II/ recipients. Therefore, while do-
nor CD4CD25 T cells required co-transplantation with synge-
neic MHC II to support donor hematopoietic progenitors, alloge-
neic recipient MHC II was required for suppression of GVHD. In
conclusion, donor CD4CD25 T cells capable of promoting
long-term engraftment and tolerance may have distinct antigenic
requirements from those responsible for GVHD suppression, and
clinical protocols for allogeneic transplantation involving
CD4CD25 T cells should account for their distinct antigenic
requirements.
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ROLE OF IL-2, IL-7, AND IL-15 IN ALLOGENEIC GRAFT-VS-LEUKEMIA
AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA IN A NOD/scid CHIMERIC
MURINE MODEL
Cipkala, D.A., Hendey, L., Boyer, M.W. Columbus Childrens Research
Institute, Columbus, OH.
We studied the GVL effects of human alloreactive CTL against
ALL in a chimeric NOD/scid mouse model. CTL were generated
from random blood donor PBMCs stimulated with the 697 human
ALL cell line and supplemented with IL-2, 7, or 15. CD8
positive T cells comprised the majority of the cultures in each
group: 46% for IL-2, 52% for IL-7, and 45% for IL-15 cultured
CTL (n  13). CTL grown in each cytokine resulted in similar in
vitro cytotoxicity: IL-2 41.3%, IL-7 37.7%, IL-15 45.3%, n 
12-15, and had statistically similar intracellular perforin and gran-
zyme-B expression. IL-7 and IL-15 CTL had statistically higher
bcl-2 levels than IL-2 CTL suggesting better anti-apoptosis and
survival potential. NOD/scid mice were injected with 697 ALL
cells followed by 5  106 CTL. Mice were sacriﬁced seven days
following CTL injection and residual leukemia was measured in
the bone marrow and spleen via ﬂow cytometry. There were two
groups of experiments with different degrees of leukemia engraft-
ment seen at day 21. In one group (low engraftment) mice not
receiving CTL had a baseline leukemia burden of 2.01% and
0.15% in the bone marrow and spleen, respectively (n  15). Mice
treated with IL-15 cultured CTL had a reduction in tumor burden
to 0.2% (n  13, P  .01) and 0.05% (n  13, P  .01) in bone
marrow and spleen, respectively. Those treated with IL-2 or IL-7
cultured CTL showed no signiﬁcant difference in leukemia burden
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